Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Jan;97(3):e9617.
doi: 10.1097/MD.0000000000009617.

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis

Wei Wei  1 , Bin Xu, Yan Wang, Chen Wu, Jingting Jiang, Changping Wu
Affiliations
Meta-Analysis

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis

Wei Wei et al. Medicine (Baltimore). 2018 Jan.

Abstract

Background: The prognostic significance of circulating soluble programmed death ligand-1 (sPD-L1) in patients with solid tumors remains unclear. We performed a meta-analysis to address this issue.

Methods: Several electronic databases were searched from January 1970 to May 2017. The hazard ratios (HRs) and 95% confidence interval (95% CI) were calculated to determine the relationship between the level of soluble PD-L1 in peripheral blood and patient overall survival.

Results: A total of 1040 patients with solid tumors from 8 eligible studies were included in the present meta-analysis. The pooled HR suggested that a high level of soluble PD-L1 (sPD-L1) in peripheral blood was significantly correlated with a worse overall survival (HR = 2.26, 95% 1.83-2.80, Z = 7.51, P < .001).

Conclusion: The present meta-analysis demonstrated that a high level of soluble PD-L1 in peripheral blood significantly predicts poor prognosis in patients with solid tumors, suggesting that high level of sPD-L1 may serve as a predictive biomarker for poor prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors disclose no conflicts of interest.

Figures

Figure 1
Figure 1
Flow diagram of study selection in the present meta-analysis.
Figure 2
Figure 2
Forest plot of studies evaluating the hazard ratios of sPD-L1 for overall survival in solid tumor patients.
Figure 3
Figure 3
Funnel plot of the included studies.
See this image and copyright information in PMC

References

    1. Topalian Suzanne L, Drake Charles G, Pardoll Drew M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450–61. - PMC - PubMed
    1. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 2014;20:5064–74. - PMC - PubMed
    1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974–82. - PMC - PubMed
    1. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 2017;389:255–65. - PMC - PubMed
    1. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26. - PMC - PubMed

Publication types